XML 24 R42.htm IDEA: XBRL DOCUMENT

Collaborative Agreements (Narrative) (Details) (USD $)			3 Months Ended				3 Months Ended
Collaborative Agreements (Narrative) (Details) (USD $)	Jun. 30, 2012	Dec. 31, 2011	Jun. 30, 2012 Takeda Agreement [Member]	Jun. 30, 2012 The Lilly Agreement [Member]	Jun. 30, 2012 The Lilly Agreement [Member] European Union Launch Of BYDUREON [Member]	Jun. 30, 2012 Alkermes Agreement [Member]	Jun. 30, 2012 Takeda Agreement [Member] Y	Oct. 30, 2009 Takeda Agreement [Member]
Collaborative Agreements [Line Items]
Percentage of shared Exenatide global development and commercialization expenses (US and outside US)				47.00%	53.00%
Lilly percentage of Exenatide global development and commercialization expenses (foreign)				100.00%
Milestone Payment						$ 7,000,000
Upfront payment received								75,000,000
Estimated development period, years							10
Deferred collaborative revenue			55,000,000
Deferred revenue, net of current portion	$ 47,500,000	$ 51,250,000	$ 47,500,000

The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References+ Details